THURSDAY, SEPTEMBER 29, 2016

GSK offers five-year price freeze on vaccines for GAVI graduating countries

GlaxoSmithKline announced on May 20 that it will support developing countries that have growing economies by putting a five year freeze on vaccine prices for countries who graduate from GAVI Alliance support.

The announcement was made by Andrew Witty, the CEO of GSK, at the GAVI Alliance replenishment launch meeting in Brussels.

The freeze means that countries graduating from GAVI Alliance support will still be able to purchase GSK vaccines for the same price that GAVI pays for up to five years after the date of graduation. According to Witty, this will help avoid creating an economic dynamic in which national resources are overstretched as countries graduate.

"We want not just to help people when they are on their knees but to continue to help them when they stand up and move forward," Witty said.

Witty also urged donors to back the Alliance's recent request for $7.5 billion in donor funding to support immunization programs in developing countries from 2016 through 2020.

"I hope governments recognize the excellent value that GAVI creates," Witty said.

GlaxoSmithKline produces more than 30 prescribed vaccines worldwide to prevent such diseases as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis.